[1]杜芬芬,梅曼,吕柳,等.蠲痹汤加减对胶原诱导性关节炎大鼠作用机制[J].陕西中医,2026,(8):1018-1023.[doi:DOI:10.3969/j.issn.1000-7369.2026.08.002]
　DU Fenfen,MEI Man,LYU Liu,et al.Mechanism of action of modified Juanbi decoction on collagen-induced arthritis rats[J].,2026,(8):1018-1023.[doi:DOI:10.3969/j.issn.1000-7369.2026.08.002]
点击复制

蠲痹汤加减对胶原诱导性关节炎大鼠作用机制

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2026年8期
页码:
1018-1023
栏目:
基础研究
出版日期:
2026-08-05

文章信息/Info

Title:
Mechanism of action of modified Juanbi decoction on collagen-induced arthritis rats
作者:
杜芬芬1; 梅曼2; 吕柳2; 霍璇3; 胡金芳3; 金玥4; 应森林5
（1.郑州大学第二附属医院，河南 郑州 450000；2.北京中医药大学东直门医院，北京 100700；3.天津天诚新药评价有限公司，天津 300301；4.天津中医药大学第一附属医院，天津 300193；5.天津中医药大学第二附属医院，天津 300250）
Author(s):
DU Fenfen1; MEI Man2; LYU Liu2; HUO Xuan3; HU Jinfang3; JIN Yue4; YING Senlin5
（1.The Second Affiliated Hospital of Zhengzhou University,Zhengzhou 450000,China;2.Dongzhimen Hospital,Beijing University of Chinese Medicine,Beijing 100700,China;3.Tianjin Tiancheng New Drug Evaluation Co.,Tianjin 300301,China;4.First Teaching Hospital of Tianjin University of Traditional Chinese Medicine,Tianjin 300193,China;5.The Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine,Tianjin 300250,China)
关键词:
类风湿关节炎; 胶原诱导性关节炎; 蠲痹汤加减; 双毒学说; 活血-免疫-抗炎; 免疫调节; 炎症因子; 血液流变学
Keywords:
Rheumatoid arthritis; Collagen-induced arthritis; Modified Juanbi decoction; Dual toxic theory; Blood circulation-immunity-anti-inflammation; Immune regulation; Inflammatory factors; Hemorheology
分类号:
R 684.3
DOI:
DOI:10.3969/j.issn.1000-7369.2026.08.002
文献标志码:
A
摘要:
目的：观察蠲痹汤加减对Ⅱ型胶原诱导性关节炎（CIA）大鼠的作用机制。方法：选取SPF级SD大鼠30只，随机分为对照组、模型组、雷公藤多苷组、蠲痹汤加减高剂量组、蠲痹汤加减低剂量组，每组6只。采用牛Ⅱ型胶原与弗氏完全佐剂乳化液诱导建立CIA模型。造模成功后，灌胃给药每日1次，连续4周。动态测量足踝肿胀度；末次给药后，检测全血黏度、血沉等血液流变学指标；称量脾脏及胸腺湿重，计算脏器系数；流式细胞术检测外周血T淋巴细胞亚群（CD3+、CD4+、CD8+）；ELISA检测血清肿瘤坏死因子-α（TNF-α）及白细胞介素-1β（IL-1β）水平；HE染色观察踝关节滑膜及软骨组织病理学变化。结果：与模型组相比，蠲痹汤加减能显著降低CIA大鼠足踝关节肿胀的宽度与厚度（P＜0.05），改善关节滑膜增生、炎性细胞浸润等病理损伤；降低高、中、低切变率下的全血黏度、红细胞聚集指数及血沉（P＜0.05）；抑制脾脏及胸腺肿大（P＜0.05）；回调CD4+/CD8+比值，下调血清TNF-α、IL-1β水平（P＜0.05）。结论：本研究以“活血-免疫-抗炎”三维调控网络，揭示蠲痹汤加减“扶正解毒、通络除痹”的作用，诠释蠲痹汤加减治疗类风湿关节炎机制。
Abstract:
Objective:To investigate mechanism of action of modified Juanbi decoction on type II collagen-induced arthritis (CIA) in rats.Methods:Thirty SPF-grade SD rats were selected and randomly divided into blank control group,model group,tripterygium glycosides group,and two dosage groups of modified Juanbi decoction (high,medium,and low doses).Each group consisted of 6 rats.The CIA model was established by inducing with bovine type II collagen and Ficoll complete adjuvant emulsion.After successful modeling,the rats were administered intragastrically once daily for 4 weeks.The swelling degree of the ankle joint was measured dynamically;after the last administration,the blood rheological parameters such as whole blood viscosity,erythrocyte aggregation index,and erythrocyte sedimentation rate were detected;the wet weights of the spleen and thymus were weighed,and the organ coefficients were calculated;the peripheral blood T lymphocyte subsets (CD3+,CD4+,CD8+) were detected by flow cytometry;the serum levels of tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β) were detected by ELISA;the pathological changes of the ankle joint synovium and cartilage tissue were observed by HE staining.Results:Compared with the model group,modified Juanbi decoction significantly reduced the width and thickness of the ankle joint swelling in CIA rats (P<0.05),improved the pathological damage such as synovial hyperplasia and inflammatory cell infiltration;significantly reduced the whole blood viscosity,erythrocyte aggregation index,and erythrocyte sedimentation rate at high,medium,and low shear rates (P<0.05);inhibited the enlargement of the spleen and thymus (P<0.05);significantly adjusted the CD4+/CD8+ ratio and downregulated the serum levels of TNF-α and IL-1β (P<0.05).Conclusion:This study,based on the “blood-activation-immune-inflammation” three-dimensional regulatory network,reveals the “strengthening the body,detoxifying,and promoting circulation to relieve arthralgia” effect of modified Juanbi decoction,and explaining mechanism of modified Juanbi decoction in the treatment of rheumatoid arthritis.

参考文献/References:

[1]BROWN P,PRATT A G,HYRICH K L.Therapeutic advances in rheumatoid arthritis[J].BMJ,2024,384：e070856.
[2]GRAVALLESE E M,FIRESTEIN G S.Rheumatoid arthritis-common origins divergent mechanisms[J].N Engl J Med,2023,388(6)：529-542.
[3]SMOLEN J S,ALETAHA D,MCINNES I B.Rheumatoid arthritis[J].Lancet,2016,388(10055)：2023-2038.
[4]国家皮肤与免疫疾病临床医学研究中心（北京协和医院）,中国医师协会风湿免疫专科医师分会,中国康复医学会风湿免疫病康复专业委员会,等.2024中国类风湿关节炎诊疗指南[J].中华内科杂志,2024,63(11)：1059-1077.
[5]吕柳,孙清露,梅曼,等.“双毒学说”在风湿痹病领域的应用研究探幽[J].现代中西医结合杂志,2023,32(3)：388-391，429.
[6]NAIR A,MORSY M A,JACOB S.Dose translation between laboratory animals and human in preclinical and clinical phases of drug development[J].Drug Dev Res,2018,79(8)：373-382.
[7]ZOU Y,ZHAO Q,ZHANG X,et al.The immunosuppressive effects and mechanisms of loureirin B on collagen-induced arthritis in rats[J].Front Immunol,2023,14：1094649.
[8]MENG M,YUE Z,CHANG L,et al.Anti-rheumatoid arthritic effects of paris saponin VII in human rheumatoid arthritis fibroblast-like synoviocytes and adjuvant-induced arthritis in rats[J].Front Pharmacol,2021,12：683698.
[9]ZHANG X,XIA J,JIANG Y,et al.2023 International consensus guidance for the use of tripterygium wilfordii hook F in the treatment of active rheumatoid arthritis[J].J Autoimmun,2024,142：103148.
[10]LV L,WANG T,LV J,et al.Tripterygium glycoside tablets combined with conventional synthetic disease-modifying antirheumatic drugs for treating rheumatoid arthritis：Protocol for a prospective multicenter open-label randomized controlled trial[J].JMIR Res Protoc,2026,15：e87156.
[11]吕柳,马悦宁,应森林.“以毒立论”在痹证治疗中的应用[J].天津中医药大学学报,2019,38(2)：164-166.
[12]梅曼,何匀曦,马玉草,等.《黄帝内经》“毒”邪思想对类风湿关节炎防治的启示[J].天津中医药,2023,40(12)：1524-1529.
[13]吕柳,陈彦竹,王奕斌,等.基于“双毒学说”治疗类风湿关节炎的长时医案分析[J].风湿病与关节炎,2020,9(8)：55-58.
[14]倪震博,孙清露,吕柳,等.应森林从“双毒学说”论治类风湿关节炎经验探析[J].中医药通报,2025,24(8)：5-7.
[15]LI J,LI L,WANG Y,et al.Systematic investigation on the anti-rheumatoid arthritis material basis and mechanism of Juan Bi Tang part 1：Integrating metabolic profiles and network pharmacology[J].J Pharm Biomed Anal,2021,202：114133.
[16]史睿,伍镝,刘新.蠲痹汤辅助艾拉莫德、甲氨蝶呤治疗类风湿关节炎疗效分析[J].中华中医药学刊,2025,43(10)：58-61.
[17]韦雯怡,罗宇东,李芳婵,等.经典名方蠲痹汤研究进展[J].中国中医基础医学杂志,2024,30(12)：2134-2140.
[18]兰佳明,黄珊,刘衍志,等.干预活性氧治疗类风湿性关节炎药物的研究进展[J].广东医科大学学报,2025,43(4)：440-446.
[19]强建红.加味蠲痹汤联合甲氨蝶呤治疗类风湿性关节炎50例[J].陕西中医,2014,35(7)：874.
[20]HELVACI N,SARI-AK D,CAM E,et al.Alterations in erythrocyte deformability aggregation and blood viscosity in rheumatoid arthritis and systemic lupus erythematosus patients：A comparative haemorheological analysis[J].Clin Hemorheol Microcirc,2025,91(1)：14-24.
[21]段艳芳,张伟红,钟志敏.类风湿关节炎患者凝血及免疫功能指标与疾病活动度的关系研究[J].中国现代药物应用,2026,20(9)：17-21.
[22]TAN J,CHEN J.Changes in peripheral blood T lymphocyte subsets predict disease progression in patients with rheumatoid arthritis[J].Am J Transl Res,2022,14(2)：1068-1075.
[23]MOON J S,YOUNIS S,RAMADOSS N S,et al.Cytotoxic CD8+T cells target citrullinated antigens in rheumatoid arthritis[J].Nat Commun,2023,14(1)：319.
[24]BUCCI L,HAGEN M,ROTHE T,et al.Bispecific T cell engager therapy for refractory rheumatoid arthritis[J].Nat Med,2024,30(6)：1593-1601.
[25]CHIN A,SMALL A,WONG S W,et al.T cell dysregulation in rheumatoid arthritis：From genetic susceptibility to established disease[J].Curr Rheumatol Rep,2025,27(1)：14.
[26]HE Z,GLASS M C,VENKATESAN P,et al.Progression to rheumatoid arthritis in at-risk individuals is defined by systemic inflammation and by T and B cell dysregulation[J].Sci Transl Med,2025,17(817)：7214.
[27]HU M,ZHOU Y,YAO Z,et al.T cell dysregulation in rheumatoid arthritis：Recent advances and natural product interventions[J].Int Immunopharmacol,2025,153：114499.
[28]李长超,柴艳梅,刘丹,等.类风湿关节炎患者血清IL-13水平表达及对外周血单个核细胞中Th17细胞亚群分化的影响[J].陕西医学杂志,2021,50(2)：197-200.
[29]温雅楠,赫吉铭,霍新慧,等.隔药饼灸对佐剂性关节炎大鼠滑膜组织相关蛋白表达的影响[J].陕西中医,2026,47(2)：147-153.
[30]WANG J,CONLON D,RIVELLESE F,et al.Synovial inflammatory pathways characterize anti-TNF-responsive rheumatoid arthritis patients[J].Arthritis Rheumatol,2022,74(12)：1916-1927.
[31]BIESEMANN N,MARGERIE D,ASBRAND C,et al.Additive efficacy of a bispecific anti-TNF/IL-6 nanobody compound in translational models of rheumatoid arthritis[J].Sci Transl Med,2023,15(681)：4419.
[32]HE C,REN Z,XIA X,et al.A single-cell RNA-seq dataset of synovial fluid from rheumatoid arthritis treated with TNF-α/JAK inhibitor[J].Sci Data,2025,12(1)：977.
[33]GREBENCIUCOVA E,VANHAERENTS S.Interleukin 6：At the interface of human health and disease[J].Front Immunol,2023,14：1255533.
[34]AVCI A B,FEIST E,BURMESTER G R.Targeting IL-6 or IL-6 receptor in rheumatoid arthritis：What have we learned?[J].Bio Drugs,2024,38(1)：61-71.
[35]KAMEDA H,MAEZAWA R,MINEGISHI Y,et al.Targeting IL-6 signaling：Safety and effectiveness in older patients with rheumatoid arthritis[J].Drugs Aging,2025,42(10)：945-951.
[36]MONACO F,DIMONTE S,JONES S A.The role of IL-6 in rheumatoid arthritis comorbidity and implications for therapy[J].Biochimica et Biophysica Acta Molecular Cell Research,2026,1873(4)：120136.
[37]梁上艳,焦晓楠,刘芳,等.心理认知重构联合拔罐疗法对单纯性肥胖儿童体育锻炼期间血脂代谢、炎症状态及肠道菌群的影响[J].保健医学研究与实践,2026,23(3):97-105.
[38]邢文珂,孙香君,马冰新,等.全身炎症聚合指数联合CURB-65评分对急诊重症肺炎患者预后的预测价值[J].保健医学研究与实践,2025,22(10):107-113.

相似文献/References:

[1]刘志队,史丽璞.加味桂枝芍药知母汤对活动期寒热错杂型类风湿关节炎患者ESR、CRP和RF调控作用分析*[J].陕西中医,2019,(1):82.
[2]倪丹红,刘 丹,吕琴琴,等.秦息痛片联合传统抗风湿药治疗早期活动性 类风湿关节炎临床研究*[J].陕西中医,2019,(4):484.
[3]刘志队,史丽璞,张铁峰.加味桂枝芍药知母汤治疗寒热错杂型类风湿关节炎临床研究*[J].陕西中医,2019,(7):906.
　LIU Zhidui,SHI Lipu,ZHANG Tiefeng..Clinical analysis of modified Guizhi Fuyao Zhimu decoction in treating cold and hot miscellaneous rheumatoid arthritis[J].,2019,(8):906.
[4]李 锐,叶冰玉△,刘佳钰,等.活血通络汤辨治类风湿关节炎合并肺间质纤维化临床研究*[J].陕西中医,2019,(8):1041.
　LI Rui,YE Bingyu,LIU Jiayu,et al.Brief analysis of Huoxue Tongluo decoction on differentiation and treatment of rheumatoid arthritis with pulmonary interstitial fibrosis[J].,2019,(8):1041.
[5]李 良,孙银娣,李亚峰,等.四妙二藤汤联合双氯芬酸钠对类风湿关节炎患者关节情况、炎症指标和复发率的影响[J].陕西中医,2019,(10):1397.
　LI Liang,SUN Yindi,LI Yafeng,et al.Effect of Simiao Erteng decoction combined with diclofenac sodium on joint condition，inflammation index and recurrence rate in patients with rheumatoid arthritis[J].,2019,(8):1397.
[6]尚 磊,刘 茜△.断藤益母汤甲氨喋呤联合对类风湿性关节炎患者DAS28评分和炎症指标的影响*[J].陕西中医,2019,(10):1400.
　SHANG Lei,LIU Qian..Effect of Duanteng Yimu decoction and methotrexate on DAS28 Score and inflammatory indicators in rheumatoid arthritis patients[J].,2019,(8):1400.
[7]刘 茜,樊亚红△,陈爱林,等.秦息痛药液外敷治疗类风湿关节炎疗效评价*[J].陕西中医,2019,(10):1403.
　LIU Qian,FAN Yahong,CHEN Ailin,et al.Evaluation of the therapeutic effect of external application of Qinxitong liquid onrheumatoid arthritis[J].,2019,(8):1403.
[8]尚磊,李映雪△.补肾通痹汤联合雷公藤多苷治疗老年类风湿关节炎疗效研究*[J].陕西中医,2019,(11):1552.
　SHANG Lei,LI Yingxue..Effect of Bushen Tongbi decoction combined with tripterygium wilfordii polyglycosides in the treatment of eldery rheumatoid arthritis[J].,2019,(8):1552.
[9]杨庆万,安 阳△,项飞燕,等.引火汤对类风湿关节炎患者骨代谢的影响*[J].陕西中医,2020,(1):73.
　YANG Qingwan,AN Yang,XIANG Feiyan,et al.Effect of Yinhuo decoction on bone metabolism in patients with rheumatoid arthritis[J].,2020,(8):73.
[10]田杰祥,王 钢,王 佳,等.中医外治法治疗类风湿关节炎滑膜炎研究进展*[J].陕西中医,2020,(1):131.
　TIAN Jiexiang,WANG Gang,WANG Jia,et al.Research progress of external treatment in the 〖JZ〗treatment of rheumatoid arthritis synovitis[J].,2020,(8):131.

备注/Memo

备注/Memo:
中央高水平中医医院临床科研业务费资助项目（DZMG-TZZX-24020）；中国中医科学院科技创新工程项目（CI2026A03810）；天津市卫生健康委员会中医中西医结合课题（2023132）
更新日期/Last Update: 2026-08-13